Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258668 | 0.98 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL18038023 | 0.94 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258594 | 0.91 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258195 | 0.91 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL25858316 | 0.90 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258406 | 0.90 | SMN1; SMN2 (0.55) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258596 | 0.89 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL23258638 | 0.89 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258994 | 0.88 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 | |
| SCHEMBL23258991 | 0.88 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPK1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | NPC1 4224/4885RAB9A 3638/4885SMN1; SMN2 111/4885 |
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | NPC1 4224/4885RAB9A 3638/4885SMN1; SMN2 111/4885 |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | NPC1 4224/4885RAB9A 3638/4885SMN1; SMN2 111/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | NPC1 4224/4885RAB9A 3638/4885SMN1; SMN2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.